Corebridge Financial’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Corebridge Financial’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,827	Closed	-$241K	–	3008
2025 Q1	$241K	Sell	1,827 -71	-4%	-$8.85K	﹤0.01%	1959
2024 Q4	$159K	Sell	1,898 -78	-4%	-$6.41K	﹤0.01%	2305
2024 Q3	$145K	Sell	1,976 -71	-3%	-$5.34K	﹤0.01%	2409
2024 Q2	$140K	Buy	+2,047	New	+$142K	﹤0.01%	2407

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Corebridge Financial's ITCI Position: Q2 2025 in Review

Corebridge Financial sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 1,827 shares — an estimated $241K sold.

Corebridge Financial first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $241K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

Corebridge Financial reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
Corebridge Financial sold 1,827 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $241K.
Corebridge Financial first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
Corebridge Financial's Intra-Cellular Therapies Inc. position peaked at $241K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.